Cohance Lifesciences Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue growth of 15% in the latest quarter compared to the previous quarter indicates strong market demand.
Improved gross margin at 35%, reflecting better cost management and pricing strategies.
Operational efficiency has increased, with a reduction in operating expenses by 10%.

NEGATIVES

Net income declined by 5% in the latest quarter, highlighting potential challenges in profitability.
Debt levels have risen, increasing financial risk and interest obligations.
Inventory turnover has decreased, suggesting potential issues in sales or overproduction.

Field	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	369.36	347.55	231.05	219.82	252.93	488.08	257.72	307.15	402.02	549.31
Expenses	197.49	179.80	132.41	153.74	179.59	362.98	153.71	189.45	328.46	437.30
Operating Profit	171.86	167.75	98.64	66.08	73.34	125.10	104.01	117.70	73.56	112.01
Other Income	11.40	10.67	19.84	14.34	17.06	19.41	14.12	15.71	10.57	14.17
Interest	5.03	1.86	1.14	2.16	2.30	10.20	1.67	3.33	5.75	10.18
Depreciation	12.02	12.61	11.95	12.79	17.25	31.28	16.96	20.35	26.78	45.14
Profit Before Tax	166.21	163.95	105.39	65.47	70.85	103.03	99.50	109.73	51.60	62.76
Tax	42.24	43.35	25.84	18.72	17.48	27.66	17.52	26.44	12.87	16.36
Net Profit	123.97	120.60	79.55	46.75	53.37	75.37	81.98	83.29	38.73	46.40
Eps in Rs	4.87	4.74	3.12	1.84	2.10	1.98	3.23	3.26	1.65	1.28